Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Sanofi's Rilzabrutinib?
Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Rilzabrutinib by Sanofi for Asthma: Likelihood of Approval
Rilzabrutinib is under clinical development by Sanofi and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Rilzabrutinib by Sanofi for Chronic Urticaria Or Hives: Likelihood of Approval
Rilzabrutinib is under clinical development by Sanofi and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData,...
Rilzabrutinib by Sanofi for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Rilzabrutinib is under clinical development by Sanofi and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData,...
Rilzabrutinib by Sanofi for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Rilzabrutinib is under clinical development by Sanofi and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According...
Rilzabrutinib by Sanofi for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Rilzabrutinib is under clinical development by Sanofi and currently in Phase II for Immunoglobulin G4-Related Disease (IgG4-RD). According to GlobalData,...